However, in cancers such as hepatoblastoma, TRPV1 signals activate and stimulate migration of vascular endothelial cells, thus creating an opposing expectation that TRPV1 antagonists may have anticancer effects [10]. This evidence concerns the gene TRPV1 and hepatoblastoma.